Hairy cell leukemia 2018_ Update on diagnosis, risk‐stratification, and treatment.pdfVIP

Received: 13 September 2017 | Revised: 4 October 2017 | Accepted: 5 October 2017 DOI: 10.1002/ajh.24936 A H A H J A N N U A L C L I N I C A L U P D A T E S I N H E M A T O L O G I C A L J M A L I G N A N C I E S Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment Xavier Troussard | Edouard Cornet Laboratoire Hematologie, CHU Caen, Abstract 14 033, Caen Cedex, France Disease overview: Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL- Correspondence V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature Xavier Troussard, Laboratoire Hematologie, CHU Caen, 14 033 Caen Cedex. lymphoid B-cell disorders, characterized by the identification of hairy cells, a specific genetic pro- Email: troussard-x@chu-caen file, a different clinical course and the need for appropriate treatment. Diagnosis: Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL immuno- logic score of 3 or 4 based on the CD11C, CD103, CD123, and CD25 expression, the trephine